.jpg?format=webp&quality=80&width=3840)
The FDA's approval of teplizumab as the first disease-modifying therapy for type 1 diabetes mellitus (T1DM) marks a significant breakthrough in its treatment. This approval is based on the understanding that T1DM can be predicted, and immune therapy can alter its progression. After years of research, this development highlights the importance of immunotherapy in T1DM. While advancements in insulins and diabetes technology have improved disease management, T1DM continues to have a high impact on life-years lost and healthcare costs. The approval of teplizumab represents a paradigm shift in T1DM treatment, offering the potential to delay the clinical onset of the disease and reduce its complications.
Like
Save
Share